Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories. Expert commentary: We foresee the development of therapeutic protocols combining these approaches with each other or conventional therapies to achieve the most appropriate guideline for management of cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1744666X.2017.1366315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Hematology, Lanzhou University Second Hospital, Lanzhou 730000, China. *Corresponding authors, E-mail:
Article Synopsis
- BTLA is an inhibitory immune checkpoint that interacts with HVEM to regulate immune balance and maintain immune tolerance on the same cell, while also affecting different immune cells to suppress immune responses.
- Dysregulation of the BTLA/HVEM interaction can lead to impaired immune cell function, allowing tumor cells to evade immune detection and progress.
- Research indicates that BTLA and HVEM are often abnormally expressed in various tumors, making them potential targets for future immunotherapy approaches in treating hematologic malignancies.
Comprehensive analysis pinpoints CCNA2 as a prognostic and immunological biomarker in non-small cell lung cancer.
BMC Pulm Med
January 2025
Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong Province, 272029, PR China.
Background: Lung cancer is a leading cause of morbidity and mortality globally. Despite advances in targeted and immunotherapies, overall survival (OS) rates remain suboptimal. Cyclin-A2 (CCNA2), known for its upregulation in various tumors and role in tumorigenesis, has an undefined function in non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFThe role of mitophagy-related genes in prognosis and immunotherapy of cutaneous melanoma: a comprehensive analysis based on single-cell RNA sequencing and machine learning.
Immunol Res
January 2025
Department of Dermatology, Shaanxi Provincial People's Hospital, Xi'an, 710068, China.
Mitophagy, the selective degradation of mitochondria by autophagy, plays a crucial role in cancer progression and therapy response. This study aims to elucidate the role of mitophagy-related genes (MRGs) in cutaneous melanoma (CM) through single-cell RNA sequencing (scRNA-seq) and machine learning approaches, ultimately developing a predictive model for patient prognosis. The scRNA-seq data, bulk transcriptomic data, and clinical data of CM were obtained from publicly available databases.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the effectiveness and safety of combining nivolumab, an immunotherapy drug, with chemotherapy in patients with a specific type of metastatic gastric cancer co-expressing FGFR2 and PD-L1.
- A total of 23 patients were treated, showing a 1-year progression-free survival (PFS) rate of 30.4% and a median overall survival (OS) of 15.1 months, though the primary endpoint of improved 1-year PFS was not achieved.
- The results highlight the need for future research on patient selection and potential combination therapies to enhance treatment outcomes in this patient population.
Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy.
Nat Commun
January 2025
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
Hypoxic tumors present a significant challenge in cancer therapy due to their ability to adaptation in low-oxygen environments, which supports tumor survival and resistance to treatment. Enhanced mitophagy, the selective degradation of mitochondria by autophagy, is a crucial mechanism that helps sustain cellular homeostasis in hypoxic tumors. In this study, we develop an azocalix[4]arene-modified supramolecular albumin nanoparticle, that co-delivers hydroxychloroquine and a mitochondria-targeting photosensitizer, designed to induce cascaded oxidative stress by regulating mitophagy for the treatment of hypoxic tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!